Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425139 | 0.87 | PTGS2 (0.83) | PTGS2PTGS1ABCB11ALDH1A1CA12 | |
| SCHEMBL6352074 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1CA12 | |
| SCHEMBL213308 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1CA1 | |
| SCHEMBL6352119 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1CA1 | |
| SCHEMBL6349469 | 0.84 | PTGS2 (0.77) | PTGS2PTGS1ABCB11CA12CA1 | |
| SCHEMBL3243184 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL213150 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1CA12 | |
| SCHEMBL7789562 | 0.83 | PTGS2 (0.78) | PTGS2PTGS1ABCB11ALDH1A1CA12 | |
| SCHEMBL6352647 | 0.82 | PTGS2 (0.80) | PTGS2PTGS1ABCB11ALDH1A1CHRNA7 | |
| SCHEMBL5608566 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-100379727-C | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-1268614-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1699347-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2005-11-23 | — | — | CN | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | disclosed |
| CN-1495170-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | G.D.ɪ����˾ | 2004-05-12 | — | — | CN | disclosed |
| US-6586603-B1 | Forming 4-(5-(4-chlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1 -yl)benzenesulfonamide used as antiinflammatory agents; side effect reduction | G.D. SEARLE & CO. | 2003-07-01 | — | — | US | disclosed |
| EP-0854723-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | SEARLE & CO (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6492411-B1 | TREATING ARTHRITIS; REDUCED SIDE EFFECTS | G. D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-6413960-B1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS; ACTIVE IN REDUCING PROSTAGLANDIN-INDUCED PAIN AND SWELLING; ANALGESICS; ANTIPYRETICS; ARTHRITIS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-07-02 | — | — | US | disclosed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885PTGS1 539/4885ABCB11 4195/4885 |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | IRAK2, IRAK4, IRAK3 | PTGS2 230/4885PTGS1 377/4885ABCB11 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.